新型雄激素受体抑制剂用于转移性激素敏感前列腺癌:当前的应用和未来的前景
Qi-Dong Xia1, Si-Han Zhang1, Na Zeng1
1Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, China.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
|November 5, 2023
概括
新型雄激素受体抑制剂 (ARi) 现在是转移性激素敏感前列腺癌 (mHSPC) 的标准,提供更好的生存率. 本综述详细介绍了ARi特性和临床试验数据,以指导一线治疗选择.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 雄激素受体 (AR) 信号传递对于前列腺癌的进展至关重要.
- 对于转移性激素敏感前列腺癌 (mHSPC) 的传统雄激素剥夺疗法 (ADT) 通常会导致耐药性.
- 新兴的新型AR抑制剂 (ARi) 代表了mHSPC治疗的重大进步.
研究的目的:
- 为mHSPC提供新型AR抑制剂的全面概述.
- 分析关键试验中的分子结构,药物特性,疗效和安全性数据.
- 为一线mHSPC治疗策略指导临床决策.
主要方法:
- 对关键临床试验的系统审查,涉及mHSPC中的新型AR抑制剂.
- 研究AR抑制剂的分子结构和药物特性分析.
- 评估有效性和安全性数据,包括疾病进展和整体存活率.
主要成果:
- 新型AR抑制剂在延缓疾病进展和延长mHSPC的存活时间方面显示出显著的益处.
- 这些药物已成为新的护理标准,与单独使用ADT相比,提供更好的结果.
- 关键试验证实了各种新型AR抑制剂的疗效和安全性.
结论:
- 新型AR抑制剂已经改变了mHSPC的第一线治疗格局.
- 了解ARi开发和应用的差异对于优化治疗选择至关重要.
- 目前正在进行的研究和III期试验将进一步完善ARi在晚期前列腺癌管理中的作用.
相关概念视频
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
190
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
190
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers
869
α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
869
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
172
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
172
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
891
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
891
Transducer Mechanism: Nuclear Receptors
1.4K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.4K


